Compare McCormick & Company, Incorporated (MKC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Neurocrine Biosciences Inc — how do they compare? McCormick & Company, Incorporated trades at $52.01 (market cap $14.04B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MKC | NBIX | |
|---|---|---|
Market Cap | $14.04B | $17.40B |
Sector | Consumer Staples | Health |
52-Week High | $72.81 | $180.55 |
52-Week Low | $45.60 | $123.10 |
Enterprise Value | $18.65B | $16.49B |
Dividend Yield | 3.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
